Neumirna Therapeutics is focused on developing innovative RNA-based therapies aimed at modifying diseases associated with neurological disorders, particularly epilepsy. The company utilizes microRNAs (miRNAs) as key regulators of gene expression, which play a crucial role in managing disease pathways. By targeting these non-coding RNAs, Neumirna aims to influence the underlying mechanisms of neurological conditions, thereby offering potential transformative treatments. Their approach highlights the significance of miRNAs in regulating gene activity and the potential for these molecules to serve as therapeutic targets.

To achieve their therapeutic goals, Neumirna employs Antisense Oligonucleotides (ASOs), which are synthetic DNA constructs designed to selectively inhibit dysregulated miRNAs. This targeted strategy allows for the modulation of disease processes at a molecular level, providing a promising avenue for treating life-threatening neurological disorders. The stability of ASOs in cellular environments ensures prolonged therapeutic effects, which is critical for achieving lasting improvements in patient outcomes. With recent funding, Neumirna is positioned to advance its research and development efforts, particularly focusing on bringing its lead candidate, NMT.001, into clinical trials.

Denmark

Developing RNA therapeutics for disease modification neurological disorders

Central Nervous System (CNS)

A.C. Meyers Vænge 15, Copenhagen, Capital Region of Denmark 2450, DK

Neumirna Therapeutics

Neumirna Therapeutics

Company Details